ISAL 2019 | Triplebodies for AML: origin, rationale & development

Name: Triplebodies for AML: origin, rationale & development
Uploaded: 2019-03-15T11:11:56.000Z
Duration: 3 min 57 s
Description: Georg Fey, PhD, of the University of Erlangen Nuremberg, Erlangen and Nuremberg, Germany, discusses the origin and rationale behind triplebodies, as well as giving an overview of triplebody agents in development. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Georg Fey • 15 Mar 2019

ISAL 2019

Acute Myeloid Leukemia Leukemia Antibodies SPM-2

Georg Fey, PhD, of the University of Erlangen Nuremberg, Erlangen and Nuremberg, Germany, discusses the origin and rationale behind triplebodies, as well as giving an overview of triplebody agents in development. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.